Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)
14.20
+1.10 (8.36%)
NASDAQ · Last Trade: Nov 3rd, 1:12 PM EST
News & Press Releases
Syndax (SNDX) Q3 2026 Earnings Call Transcriptfool.com
Revenue surged 82% year-over-year as Revuforj and Niktimvo drive commercial momentum.
Via The Motley Fool · November 2, 2026
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Callmarketbeat.com
Syndax Pharmaceuticals (NASDAQ:SNDX) reported third-quarter 2026 total revenue of $83.3 million, an 82% increase from the prior-year period, as sales of its Revuforj leukemia treatment and collaboration revenue from Niktimvo continued to rise.
Revuforj net revenue reached $60.7 million during the q
Via MarketBeat · November 2, 2026
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition -
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · November 2, 2026
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · November 2, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimateschartmill.com
Via Chartmill · August 4, 2026
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · October 30, 2026
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · October 30, 2026
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · October 26, 2026
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (“Syndax” or “the Company”) (NASDAQ: SNDX) for violations of the securities laws.
By Schall, Brown & Schwartz LLP · Via Business Wire · October 17, 2026
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · October 15, 2026
What's going on in today's after hours sessionchartmill.com
Via Chartmill · October 12, 2026
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
– Trial did not meet the primary endpoint of annualized rate of FVC decline –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · October 12, 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · October 2, 2026
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · September 1, 2026
Syndax (SNDX) Q2 2026 Earnings Call Transcriptfool.com
Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo.
Via The Motley Fool · August 11, 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · August 5, 2026
Syndax Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.
Chief Executive Officer Michael Metzger said the
Via MarketBeat · August 4, 2026
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
– Total revenue of $73 million in 2Q26, a 92% year-over-year increase –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · August 4, 2026
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · July 28, 2026
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Pushmarketbeat.com
Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis.
Chief Executive Officer Michael Metzger said the company is now
Via MarketBeat · July 14, 2026
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · July 14, 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · July 1, 2026
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · June 11, 2026
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · June 11, 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · June 4, 2026